Animab is developing antibodies that can be administered orally to animals.
Animab has raised €10M across 1 funding round from 6 investors, most recently a Series A round in Nov 2022. Based in Ghent, Belgium; active in Agritech. Data as of 7 Aug 2026.
Timing: overdue vs cohort gap · momentum unknown. Funding-only estimates, not predictions and not investment advice — see signals.
| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2022-11-09 | Series A | €10M |
| AIF,PMV,Qbic III ,Seventure Partners,V-Bio Ventures,VIB |
| View deal → |
